Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

the press release.

GAAP net loss for the nine months ended September 30, 2009 was $5.2 million ($0.05 per diluted share), compared to GAAP net income of $6.3 million ($0.06 per diluted share) for the nine months ended September 30, 2008. Non-GAAP net income was $33.9 million ($0.33 per diluted share) for the nine months ended September 30, 2009, compared to non-GAAP net income of $21.9 million ($0.21 per diluted share) for the nine months ended September 30, 2008.

As of September 30, 2009, BioMarin had cash, cash equivalents and short and long-term investments totaling $491.8 million.

"During the quarter, we continued to advance our clinical pipeline as we completed enrollment for the Phase I/II study of GALNS for MPS IVA and initiated the Phase II trial of PEG-PAL for PKU. On the commercial front, we were issued patents covering stable tablet formulation and the once daily dosing regimen for Kuvan, and received claims covering the approved administration of Kuvan with food. We believe that these patents are significant in extending protection beyond orphan drug market exclusivity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "Based on our performance to date, we have narrowed the guidance range on a few items to reflect increased visibility into the year, including improved expectations for the bottom line. Our commercial products are performing well, and we continue to carefully manage expenses. We are also carefully evaluating both internal pipeline programs and external product opportunities to maximize long-term value for both the company and our shareholders. Also, as announced earlier this week, we acquired Huxley Pharmaceuticals, which is developing a proprietary form of 3,4-DAP for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome. A positive opinion was issued by the EMEA last week, and we expect to launch this product in the EU in the first quarter of 2010. This low-risk deal le
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, ... stem cell-derived islet replacement therapy for the treatment of ... Dr. Eugene Brandon , Director of Strategic Relations ... annual summit showcases the latest in type 1 diabetes ... presentation are as follows: , , , ...
(Date:3/3/2015)... MOUNTAIN VIEW, Calif. , March 3, 2015 ... the enhanced drug discovery market, Frost & Sullivan ... Frost & Sullivan Award for Technology Leadership. Neopeutics ... offering clients a robust, cost-effective, and easily adaptable ... on agents that are catalogued as failing compounds ...
(Date:3/3/2015)... Colo. , March 3, 2015  Cannabis Science, ... development of cannabis-based medicine, today announced two important developments: ... its multiple global product launches, and CEO Raymond ... the Chicago HR Examiner. In the article, ... about leading a company in an industry that ...
Breaking Medicine Technology:ViaCyte to Present at JDRF TypeOneNation Research Summit 2Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 2Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 3Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 4Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 5CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 2CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 3CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 4CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 5
(Date:3/4/2015)... San Jose, CA (PRWEB) March 04, 2015 ... products produced by companies whose management forgot – or ... assessing potential value: Validate the market based on physician ... “We've seen companies – more specifically, founders – become ... to answer the key question: Will physicians use the ...
(Date:3/3/2015)... As payers pledge to move the bulk ... next few years, they are testing various initiatives to ... care spending they control — involved. The March issue ... tracks some of the strategies proposed by industry ... organization (ACO)-type model. , One way to get specialists ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... to NOVAtime SaaS Workforce Management / Time ... and attendance processes. , Since 2004, Innovative ... developmental disabilities with the best quality of life. ...
(Date:3/3/2015)... Loma Linda University Health announced today, that ... it will be offering new, healthier choices in all ... the past year, a cross-section of Loma Linda University ... listening to vendors, sampling their products, and ultimately recommending ... Most recently, a food fair was held during which ...
(Date:3/3/2015)... Sacramento, CA (PRWEB) March 03, 2015 ... cancers. , Researchers at UC Davis have developed and ... of cancer cells, causing them to self-destruct. This novel ... – responsible for a usually fatal type of brain ... aggressive cancers. , The article, to be published ...
Breaking Medicine News(10 mins):Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
... AMA President, Dr Mukesh Haikerwal, said today that the Government ... the Health Budget if it allowed GPs to refer patients ... details of the proposal are contained in the AMA's Federal ... ,Dr Haikerwal said GPs currently have to refer patients to ...
... burn out. Apart from it affecting productivity in one's job, ... Scientists. //This study supports the various academic endeavors which has ... pressure, metabolic syndrome, flu, and heart disease. ,A ... Type 2 Diabetes was almost 1.8 times pronounced in people ...
... of Obstetrics, Gynecology & Reproductive Sciences at Yale School ... report that women who are into regular bicycling experienced ... of pain in the genitals. , ... competitive cyclists and 22 women runners. With the help ...
... Jennifer Aniston says yoga helped her deal with her split from ... to get her mind and body back in shape, according to ... to move" before she commenced with yoga and adds, "I was ... to songs by Seal, Coldplay, The Rolling Stones and Alicia Keyes ...
... syringes are the main reasons for the rise in HIV infections ... and Chennai, states a new study. ,"Poor knowledge of ... with men. In Bangalore, for example, three in four men who ... transmitted, and a large proportion of them engaged in unprotected sex ...
... would thrill every gourmet. It is great reading//,that will surely ... a full course meal, daubed in rich, saucy humor, without ... is the brain behind this unique literary piece, who is ... Laboratory. Truly a gourmet, who enjoys every kind of food, ...
Cached Medicine News:Health News:Competitive women cyclists experience reduced genital sensation 2Health News:Homosexuality, drug abuse increasing HIV in India: study 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 3
This ENDOLOOP suture has a suture type - 0 Coated VICRYL and a 1.5 inch diameter....
... ligature inserted into a plastic tube. The plastic tube ... other. The suture protrudes from the narrow end and ... which becomes secure after the device is activated. The ... scored end of the plastic tube. The scored end ...
... is an enzyme immunoassay used for the ... dehydrogenase) and toxin A in human fecal ... aid in the diagnosis of C. difficile ... Triage Microbiology product line, designed to help ...
... VIDAS tests are presented in individual, ready ... a strip and a SPR. The strip ... (buffer, conjugate and substrate.) The SPR (Solid ... Its inside surface is coated with the antigen ...
Medicine Products: